Loading company…
Neuren Pharmaceuticals, based in Melbourne, Australia, develops therapeutics for neurodevelopmental disorders, led by NNZ-2591.
Its lead candidate, NNZ-2591, is aimed at Pitt-Hopkins syndrome, and the company works with pharmaceutical firms and research institutions. Founded in 2000, it completed an IPO in February 2005 and has engaged in 3 significant deals. A PIPE funding round raised USD 21.50 mn, which is also its total raised. Reported revenue was USD 154.12 mn in 2023.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in